Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its... see more

Recent & Breaking News (NDAQ:CASI)

CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer

PR Newswire May 18, 2017

CASI Pharmaceuticals Reports First Quarter 2017 Financial Results

PR Newswire May 15, 2017

CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer

PR Newswire April 14, 2017

CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results

PR Newswire March 31, 2017

CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting

PR Newswire March 28, 2017

CASI Pharmaceuticals' Import Drug Registration Application For EVOMELA® Accepted For Review By CFDA

PR Newswire December 5, 2016

CASI Pharmaceuticals Reports Third Quarter 2016 Financial Results

PR Newswire November 14, 2016

12 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  August 16, 2016

CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC)

PR Newswire June 1, 2016

CASI Pharmaceuticals Reports First Quarter 2016 Financial Results

PR Newswire May 13, 2016

NorthStar Realty Europe Announces First Quarter 2016 Results

PR Newswire May 13, 2016

CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)

PR Newswire May 12, 2016

James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development

PR Newswire April 18, 2016

CASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results

PR Newswire March 28, 2016

CASI Pharmaceuticals Announces Initial Closing Of Its Strategic Financing With Receipt Of $10.3 Million Proceeds

PR Newswire January 19, 2016

CASI Pharmaceuticals' Import Drug Registration Application For MARQIBO® Accepted For Review By CFDA

PR Newswire January 12, 2016

CASI Pharmaceuticals Reports Third Quarter 2015 Financial Results

PR Newswire November 13, 2015

Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference

PR Newswire November 8, 2015

Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting

PR Newswire November 5, 2015

CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma (FLC)

PR Newswire November 4, 2015